evaluate the pharmaceuticals company saxenda on amgen and glp-1 Amgen's obesity drug may help patients keep weight off GLP-1 analogs, new trend in

M.AlagawanyM.Abdel-MoneimA.-M

As more real-world data becomes available in 2026, we expect the official literature to become more specific about the potential for anxiety

Medicamentos para la depresin, trastornos psiquitricos o la ansiedad

placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial

One major study published in early 2025, which followed over 351,000 adults, found no statistically significant increase in the long-term risk of thyroid cancer for those taking GLP-1 medications compared to those on other diabetes drugs

Some benefits of FDA-approved GLP-1/GIP medications beyond weight loss are supported by emerging research and may vary based on individual health conditions, including: Improve blood sugar regulation, increase insulin sensitivity, and lower A1C Reduce long-term diabetic risks and protect pancreatic function Lower cholesterol, triglycerides, and blood pressure, supporting long-term cardiovascular health Show promising reductions in heart attacks and strokes in early studies Reduce liver fat and potentially improve metabolic fatty liver disease